Harmony Biosciences CEO Dayno to retire, COO to take over; shares fall

By Reuters News

** Shares of Harmony Biosciences HRMY.O fall nearly 4% to $38.79

** Co says COO Peter Anastasiou will become president and CEO on Jan 1, 2027

** Anastasiou succeeds Jeffrey Dayno, CEO since 2023, who will retire and leave the board on Dec 31

** Anastasiou previously led Capsida Biotherapeutics as CEO for nearly four years

** Co reaffirms FY26 WAKIX net revenue forecast of $1.0 bln-$1.04 bln; says BP-205 MAD study data remain on track for Q4

** 7 of 11 brokerages rate the stock "buy" or above, 3 "hold" and 1 "sell"; median PT - $50 - data compiled by LSEG

** As of last close, stock has risen 7.64% YTD

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk